CAMBRIDGE, England–(BUSINESS WIRE)–Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced today the second closing of…
Author: Business Wire
Prime Healthcare Services, Inc. Announces Closing of $225 Million Add-on Senior Secured Notes Offering
ONTARIO, Calif.–(BUSINESS WIRE)–Prime Healthcare Services, Inc. (Prime), an award-winning national health system with 31 hospitals, announced that it has closed its public offering of $225 million Add-on senior secured credit notes – above the initia…
jCyte, Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte Inc. Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy
Gyroscope Therapeutics Announces Launch of Initial Public Offering
LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics announces launch of initial public offering.
Midwest Vision Partners Announces Partnership With Balian Eye Center
CHICAGO & ROCHESTER, Mich.–(BUSINESS WIRE)– #eyecare–Midwest Vision Partners Announces Partnership With Balian Eye Center
OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCell–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated inter…
Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has rec…
Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, announced today that the following paper presentation, highlighting pre…
Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of supportive preclinical d…
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today …
KOVR — New Edmonton-Developed VR Software Helping Diabetes Patients Now Being Tested on Ophthalmology Patients
EDMONTON, Alberta–(BUSINESS WIRE)–Local VR developer begins beta testing its new software platform, Stratos, in limited clinical testing.
National Vision is Named One of America’s Best Employers for Diversity by Forbes
DULUTH, Ga.–(BUSINESS WIRE)—- $EYE–National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, announced today that it has been recognized as one of Forbes’ Best Em…
First Segment of Kopin’s Three Part Webinar Series "AR and VR: The Paradigm Shift to Smartglasses Starts Now" Draws Over 300 Participants
WESTBOROUGH, Mass.–(BUSINESS WIRE)–Kopin® Corporation (NASDAQ: KOPN), a leading developer and provider of transmissive and reflective active matrix liquid crystal and organic light emitting diode (OLED) microdisplays used in military, enterprise, ind…
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announc…
NovaBay Pharmaceuticals to Hold First Quarter 2021 Conference Call on May 6
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three months ended March 31, 2021 after market close on Thursday, May 6, 2021 and will hold an investment commun…
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Q-State Biosciences Presents at the 2021 Neuroimmunology Drug Development Summit
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Q-State Biosciences announces new data presented at the 2021 Neuroimmunology Drug Development Summit.
Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
GENEVA–(BUSINESS WIRE)–Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza